

POSTER PRESENTATION

Open Access

Cardiac involvement and clinical follow up of patients with hereditary transthyretin related amyloidosis associated with Glu89Gln mutation

Mariana Gospodinova^{1*}, Stayko Sarafov², Velina Guergueltcheva³, Andrey Kirov⁴, Teodora Chamova², Albena Todorova⁴, Ivailo Tournev², Stefan Denchev¹

From First European Congress on Hereditary ATTR amyloidosis Paris, France. 2-3 November 2015

Background

Cardiac involvement is common in hereditary transthyretin – related amyloidosis (ATTR), but there is a significant phenotypic heterogeneity depending on the mutation.

Patients and methods

We evaluated forty consecutive ATTR patients with Glu89Gln mutation, focusing on cardiac involvement - 18 male, 22 female at a mean age of 57.6±6,7 years. A clinical examination, 12–channel ECG, conventional 2D, Doppler and tissue Doppler echocardiography were performed. The patients were followed for 36 months in the range from 2 to 78 months.

Results

Median age of symptoms development was 52, 3±6, 4 years. Cardiac onset was found in 5 (12,5%) patients. Cardiomyopathy and peripheral polyneuropathy were evident at diagnosis in all patients. Echocardiography revealed a significant increase in wall thickness of both left and right ventricles (septum – 18,6±3,4 mm; posterior wall – 17,5±2,5 mm; RV free wall – 8,4±2,0 mm). Varying degrees of LV diastolic dysfunction were found – Grade 1 in 11 (27,5%) patients, Grade 2 in 12 (30%) and Grade 3 in 17 (42,5%) patients. A reduced LV ejection fraction was found in 9 (22,5%) patients. A common finding were significantly reduced mitral annular systolic velocities (s'septum-5,4±2,0 cm/s, s lat.-5,7±1,9 cm/s), registered in all the evaluated patients, pointing to an impaired LV longitudinal

systolic function. The systolic myocardial velocities of the tricuspid annulus and TAPSE values were reduced respectively 6,9±2,1cm/s and 12,8±3 mm in 14 of the patients (35%). Pericardial effusion was found in 13 (32,5%) patients.

Pathological ECG was present in 35(87,5%) of the evaluated patients. Atrial fibrillation was registered in 4 (10%) patients, A-V block first degree in 8 (20%), low voltage in 15 (37,5%), left bundle branch block in 3 (7,5%), left anterior fascicular block in 9 (22,5%), pathological Q wave in 14 (35%), right bundle branch block in 2 (5%), and pace-maker rhythm in 2 (5%). Rhythm and conduction disturbances on ECG were found in 24 patients (60%).

The following events occurred during the follow-up period: two deaths (5,4%) (one patient due to ischemic stroke; and another due to heart failure). Two other patients suffered from ischemic strokes. 24-hour Holter ECG revealed short periods of atrial fibrillation and an oral anticoagulant was initiated. A sinus pause > 3 s was observed in one of the patients and a permanent pacemaker was implanted. Four new cases (10%) with symptomatic heart failure, requiring diuretic treatment were observed. In 15 patients a worsening of the symptoms from the peripheral neuropathy were found.

Conclusion

Our study confirms that ATTR associated with the Glu89Gln mutation has a mixed phenotype – neurological and cardiac and an unfavorable prognosis. Our findings imply that patients and carriers of Glu89Gln require close multidisciplinary (both cardiological and neurological) follow-up in order to initiate treatment in time.

Full list of author information is available at the end of the article



¹Medical Institute of Ministry of Interior, Clinic of Cardiology, 1606, Sofia, Bulgaria

Authors' details

¹Medical Institute of Ministry of Interior, Clinic of Cardiology, 1606, Sofia, Bulgaria. ²University Hospital Alexandrovska, Clinic of Neurology, 1431, Sofia, Bulgaria. ³University Hospital Sofiamed, Neurology Department, 1528, Sofia, Bulgaria. ⁴Genetic lab, Genika, 1113, Sofia, Bulgaria.

Published: 2 November 2015

doi:10.1186/1750-1172-10-S1-P54

Cite this article as: Gospodinova *et al.*: Cardiac involvement and clinical follow up of patients with hereditary transthyretin related amyloidosis associated with Glu89Gln mutation. *Orphanet Journal of Rare Diseases* 2015 10(Suppl 1):P54.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

